Cargando…
Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019
BACKGROUND & AIMS: Although incidence rates of hepatocellular carcinoma (HCC) began to decline in the United States in the past decade, disparities in rates among racial/ethnic groups have persisted. Whether disparities in stage at diagnosis have remained over time, however, is unclear. METHODS:...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550401/ https://www.ncbi.nlm.nih.gov/pubmed/37799980 http://dx.doi.org/10.1016/j.jhepr.2023.100868 |
_version_ | 1785115524085055488 |
---|---|
author | Alvarez, Christian S. Ruhl, Jennifer Flynn, Gretchen Graubard, Barry I. McGlynn, Katherine A. |
author_facet | Alvarez, Christian S. Ruhl, Jennifer Flynn, Gretchen Graubard, Barry I. McGlynn, Katherine A. |
author_sort | Alvarez, Christian S. |
collection | PubMed |
description | BACKGROUND & AIMS: Although incidence rates of hepatocellular carcinoma (HCC) began to decline in the United States in the past decade, disparities in rates among racial/ethnic groups have persisted. Whether disparities in stage at diagnosis have remained over time, however, is unclear. METHODS: National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program has created a new staging-over-time variable that facilitates the examination of trends in HCC stage. Thus, the proportions of HCCs diagnosed by stage between 1992 and 2019 were examined among non-Hispanic White, non-Hispanic Black (NHB), Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native (AI/AN) individuals. HCC incidence between 1992 and 2019 was also analysed using Joinpoint regression. RESULTS: Between 1992 and 2019, the proportion of stage 1 HCCs increased and the proportion of stage 4 HCCs decreased among non-Hispanic White, NHB, Hispanic, and Asian/Pacific Islander individuals. Among AI/AN persons, the proportion of stage 1 tumours remained stable, and the proportion of stage 4 tumours declined. In the most recent time period, NHB individuals had the lowest proportions of stage 1 HCCs (32%) and the highest proportion of stage 4 HCCs (20%) of any group. Joinpoint analysis found that HCC incidence began to decline by 2013 among all groups except AI/AN individuals, the only group that had an increase in incidence. CONCLUSIONS: Despite generally favourable trends in HCC stage and incidence rates, disparities remain. NHB persons continue to have less favourable stages at diagnosis, and incidence rates continue to increase among AI/AN persons. IMPACT AND IMPLICATIONS: HCC incidence rates among most United States racial/ethnic groups began to decline in recent years, but whether stage at diagnosis also improved was unclear. As a result, a new SEER stage variable was used to examine stage trends by race/ethnicity. Although the finding of generally favourable trends in stage as well as incidence is encouraging, continuity disparities in both stage and incidence require serious attention. |
format | Online Article Text |
id | pubmed-10550401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-105504012023-10-05 Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 Alvarez, Christian S. Ruhl, Jennifer Flynn, Gretchen Graubard, Barry I. McGlynn, Katherine A. JHEP Rep Short Communication BACKGROUND & AIMS: Although incidence rates of hepatocellular carcinoma (HCC) began to decline in the United States in the past decade, disparities in rates among racial/ethnic groups have persisted. Whether disparities in stage at diagnosis have remained over time, however, is unclear. METHODS: National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program has created a new staging-over-time variable that facilitates the examination of trends in HCC stage. Thus, the proportions of HCCs diagnosed by stage between 1992 and 2019 were examined among non-Hispanic White, non-Hispanic Black (NHB), Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native (AI/AN) individuals. HCC incidence between 1992 and 2019 was also analysed using Joinpoint regression. RESULTS: Between 1992 and 2019, the proportion of stage 1 HCCs increased and the proportion of stage 4 HCCs decreased among non-Hispanic White, NHB, Hispanic, and Asian/Pacific Islander individuals. Among AI/AN persons, the proportion of stage 1 tumours remained stable, and the proportion of stage 4 tumours declined. In the most recent time period, NHB individuals had the lowest proportions of stage 1 HCCs (32%) and the highest proportion of stage 4 HCCs (20%) of any group. Joinpoint analysis found that HCC incidence began to decline by 2013 among all groups except AI/AN individuals, the only group that had an increase in incidence. CONCLUSIONS: Despite generally favourable trends in HCC stage and incidence rates, disparities remain. NHB persons continue to have less favourable stages at diagnosis, and incidence rates continue to increase among AI/AN persons. IMPACT AND IMPLICATIONS: HCC incidence rates among most United States racial/ethnic groups began to decline in recent years, but whether stage at diagnosis also improved was unclear. As a result, a new SEER stage variable was used to examine stage trends by race/ethnicity. Although the finding of generally favourable trends in stage as well as incidence is encouraging, continuity disparities in both stage and incidence require serious attention. Elsevier 2023-07-29 /pmc/articles/PMC10550401/ /pubmed/37799980 http://dx.doi.org/10.1016/j.jhepr.2023.100868 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Short Communication Alvarez, Christian S. Ruhl, Jennifer Flynn, Gretchen Graubard, Barry I. McGlynn, Katherine A. Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title | Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title_full | Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title_fullStr | Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title_full_unstemmed | Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title_short | Trends in hepatocellular carcinoma stage by racial/ethnic group in the United States, 1992–2019 |
title_sort | trends in hepatocellular carcinoma stage by racial/ethnic group in the united states, 1992–2019 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550401/ https://www.ncbi.nlm.nih.gov/pubmed/37799980 http://dx.doi.org/10.1016/j.jhepr.2023.100868 |
work_keys_str_mv | AT alvarezchristians trendsinhepatocellularcarcinomastagebyracialethnicgroupintheunitedstates19922019 AT ruhljennifer trendsinhepatocellularcarcinomastagebyracialethnicgroupintheunitedstates19922019 AT flynngretchen trendsinhepatocellularcarcinomastagebyracialethnicgroupintheunitedstates19922019 AT graubardbarryi trendsinhepatocellularcarcinomastagebyracialethnicgroupintheunitedstates19922019 AT mcglynnkatherinea trendsinhepatocellularcarcinomastagebyracialethnicgroupintheunitedstates19922019 |